ASRT Assertio Therapeutics: Earnings per share for the trailing year

The current share price of Assertio Holdings, Inc. (ASRT) shown on this chart confirms the efficiency of outsourcing production via third-party US plants to eliminate unnecessary expenses. The company is currently shifting its strategic focus and cutting costs to return to profitability. Since demand for neurological drugs remains stable and decoupled from economic trends, the EPS stands at -15.50, highlighting the defensive qualities of this business.
Financial and market metric breakdowns for Assertio (ASRT)

Year-over-year (YoY) EPS growth (TTM) measures the annual trend of net income per share over twelve months, reflecting the efficiency of profit generation per share. By analyzing this EPS YoY TTM relative change chart, an investor assesses capital sensitivity to financial reporting, which for Assertio Holdings, Inc. (ASRT) confirms the successful integration of acquired pharma brands and the synergy of distributing neurology drugs.